Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Maze Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC for a registered public offering of 5,540,000 shares of common stock at $23.50 per share and pre-funded warrants to purchase 850,000 shares at $23.499 per warrant. The company expects gross proceeds of $150 million and estimates net proceeds of about $144.7 million after fees and expenses.
The pre-funded warrants carry a $0.001 per share exercise price and are exercisable any time, subject to beneficial ownership caps generally at 4.99% or 9.99%, adjustable up to 19.99% with advance notice. Maze plans to use the funds primarily to advance its clinical-stage programs MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, and for general corporate purposes. The company states that, with these proceeds and existing cash and investments, it expects to fund operations into 2029.
Maze Therapeutics, Inc. is conducting a primary offering of 5,540,000 shares of common stock and pre-funded warrants to purchase 850,000 shares of common stock, as set forth in the prospectus supplement. The offering price is $23.50 per share (pre-funded warrant exercise price $0.001). Estimated gross proceeds are $150.16M and estimated net proceeds to the company are approximately $144.7M after underwriting discounts. The company reported 49,335,551 shares outstanding as of December 31, 2025. Proceeds are intended to fund R&D (including MZE829 and MZE782) and general corporate purposes; management has broad discretion over use of proceeds.
Maze Therapeutics executive Harold Bernstein, President, R&D & CMO, exercised stock options to acquire 15,000 shares of common stock at an exercise price of $10.42 per share on April 1, 2026. He then sold the same 15,000 shares in open-market transactions at weighted average prices of $29.24, $30.06, and $31.07 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. Following these transactions, his direct common stock holdings from this block were reduced to zero, while he continued to hold 237,407 stock options after the exercise.
Maze Therapeutics SVP of Finance Amy Bachrodt exercised stock options and sold shares in a planned transaction. She exercised options to acquire 2,500 shares of Common Stock at $10.42 per share, then sold a total of 2,500 shares in open-market trades at weighted average prices of $29.3227 and $30.3367 per share. These sales were executed under a Rule 10b5-1 trading plan adopted on September 29, 2025. Following the transactions, she directly owns 12,965 shares of Common Stock.
Maze Therapeutics CSBO Atul Dandekar reported an exercise-and-sell transaction in company stock. On March 30, 2026, he exercised 7,500 stock options at $10.42 per share, acquiring an equal number of Maze Therapeutics common shares.
That same day, he sold a total of 7,500 common shares in two open-market transactions at weighted average prices of $29.2556 and $30.0173 per share, executed under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owns 10,503 common shares and holds 51,643 stock options that remain outstanding.
Maze Therapeutics, Inc. ownership disclosure: Paradigm BioCapital Advisors LP group reports beneficial ownership stakes in Common Stock as of March 25, 2026. The filing lists 3,051,087 shares (6.1%) held by Paradigm BioCapital Advisors/related reporting persons and 2,688,520 shares (5.4%) held by Paradigm BioCapital International Fund Ltd. Shares outstanding were 49,708,658 as of March 20, 2026.
The filing clarifies voting and dispositive power is sole for the reported shares and includes a joint filing agreement signed by the reporting persons.
Maze Therapeutics director Neil Kumar received a grant of stock options to buy 33,417 shares of Common Stock. The options carry an exercise price of $30.38 per share and expire on March 26, 2036. They vest in 36 equal monthly installments starting April 27, 2026, contingent on his continued service.
Maze Therapeutics, Inc. director Neil Kumar has filed an initial Form 3, identifying himself as a reporting person for the company’s stock. The filing lists no reportable transactions or holdings, with all transaction counts and share amounts in the transaction summary shown as zero.
MAZE: Notice of proposed sale of 30,000 common shares via option exercise. The filing lists 30,000 shares to be sold on 03/30/2026 through the exercise of stock options for cash. The record shows two prior 10b5-1 sales by Atul Dandekar: 7,500 shares on 02/27/2026 for $340,722.75 and 7,500 shares on 01/29/2026 for $331,990.50. The filing references 49,708,658 shares outstanding as of 03/30/2026.
Maze Therapeutics files its annual report outlining rapid progress in kidney and metabolic disease programs built on its human genetics–driven Compass platform. The company is a clinical-stage biopharma with no product revenue, focused on small‑molecule precision medicines.
Lead candidate MZE829, an APOL1 inhibitor for APOL1‑mediated kidney disease, showed positive Phase 2 proof‑of‑concept data, with a 35.6% mean reduction in urinary albumin‑to‑creatinine ratio at week 12 in evaluable patients and larger reductions in key subgroups. Maze plans to continue Phase 2 enrollment and move into pivotal development.
MZE782, targeting SLC6A19, completed a Phase 1 trial in healthy volunteers, was well tolerated, and produced large, dose‑dependent increases in urinary phenylalanine excretion, supporting Phase 2 trials in phenylketonuria and chronic kidney disease planned for 2026. The report also highlights partnered programs, including MZE001 for Pompe disease, licensed to Shionogi with a $150 million upfront payment, and neurology and ophthalmology collaborations that validate the Compass platform and diversify potential future revenue.
Maze Therapeutics files its annual report outlining rapid progress in kidney and metabolic disease programs built on its human genetics–driven Compass platform. The company is a clinical-stage biopharma with no product revenue, focused on small‑molecule precision medicines.
Lead candidate MZE829, an APOL1 inhibitor for APOL1‑mediated kidney disease, showed positive Phase 2 proof‑of‑concept data, with a 35.6% mean reduction in urinary albumin‑to‑creatinine ratio at week 12 in evaluable patients and larger reductions in key subgroups. Maze plans to continue Phase 2 enrollment and move into pivotal development.
MZE782, targeting SLC6A19, completed a Phase 1 trial in healthy volunteers, was well tolerated, and produced large, dose‑dependent increases in urinary phenylalanine excretion, supporting Phase 2 trials in phenylketonuria and chronic kidney disease planned for 2026. The report also highlights partnered programs, including MZE001 for Pompe disease, licensed to Shionogi with a $150 million upfront payment, and neurology and ophthalmology collaborations that validate the Compass platform and diversify potential future revenue.